Atara Biotherapeutics (ATRA) to Release Earnings on Friday

Atara Biotherapeutics (NASDAQ:ATRA) is projected to release its Q4 2025 results before the market opens on Friday, March 6th. Analysts expect Atara Biotherapeutics to post earnings of ($0.68) per share and revenue of $0.70 million for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, March 13, 2026 at 10:30 AM ET.

Atara Biotherapeutics Stock Performance

Shares of Atara Biotherapeutics stock opened at $5.26 on Friday. The stock has a market capitalization of $37.92 million, a P/E ratio of 2.41 and a beta of -0.43. Atara Biotherapeutics has a 52-week low of $3.92 and a 52-week high of $19.15. The stock’s 50-day simple moving average is $8.72 and its 200 day simple moving average is $11.95.

Insiders Place Their Bets

In other Atara Biotherapeutics news, major shareholder Innovation Ltd Panacea sold 80,554 shares of the company’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $6.07, for a total value of $488,962.78. Following the transaction, the insider directly owned 1,324,446 shares in the company, valued at $8,039,387.22. This represents a 5.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 4.00% of the company’s stock.

Hedge Funds Weigh In On Atara Biotherapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of ATRA. Geode Capital Management LLC boosted its stake in shares of Atara Biotherapeutics by 2.5% during the second quarter. Geode Capital Management LLC now owns 60,136 shares of the biotechnology company’s stock valued at $464,000 after purchasing an additional 1,457 shares during the period. Marshall Wace LLP bought a new stake in Atara Biotherapeutics during the 2nd quarter valued at $327,000. Raymond James Financial Inc. bought a new stake in Atara Biotherapeutics during the 2nd quarter valued at $31,000. Vanguard Group Inc. boosted its position in Atara Biotherapeutics by 6.6% during the 3rd quarter. Vanguard Group Inc. now owns 203,438 shares of the biotechnology company’s stock valued at $2,915,000 after buying an additional 12,677 shares during the period. Finally, Mackenzie Financial Corp grew its holdings in Atara Biotherapeutics by 183.5% in the 3rd quarter. Mackenzie Financial Corp now owns 63,816 shares of the biotechnology company’s stock worth $914,000 after acquiring an additional 41,302 shares during the last quarter. 70.90% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Canaccord Genuity Group reissued a “hold” rating and issued a $6.00 price target (down from $25.00) on shares of Atara Biotherapeutics in a research report on Tuesday, January 13th. New Street Research set a $6.00 target price on shares of Atara Biotherapeutics in a report on Tuesday, January 13th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Atara Biotherapeutics in a research report on Monday, December 29th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Atara Biotherapeutics currently has an average rating of “Reduce” and an average target price of $6.00.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a biotechnology company focused on the discovery, development and commercialization of novel T-cell immunotherapies to transform the treatment of cancer and autoimmune disease. Headquartered in South San Francisco, California, Atara leverages its proprietary off-the-shelf allogeneic Epstein-Barr virus (EBV)-directed T-cell platform to generate engineered cell therapies designed to target EBV-driven malignancies and immune-mediated disorders.

The company’s lead product candidate, tabelecleucel, is an off-the-shelf, EBV-specific T-cell therapy in clinical development for the treatment of EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers.